Yu Shi-Tong, Huang Da, Xiong Chengfeng, Xie Rong, Yu Jichun
Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Department of Thyroid Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Oral Oncol. 2025 Feb;161:107140. doi: 10.1016/j.oraloncology.2024.107140. Epub 2024 Dec 17.
Locally advanced papillary thyroid carcinoma (PTC) with RET fusion-positive poses significant challenges for surgical resection due to tumor invasion into critical structures. Neoadjuvant targeted therapies are a promising approach to reduce the tumor burden and improve the resectability. Selperctinib, a RET kinase inhibitor, has been approved for the treatment of advanced or metastatic RET-altered thyroid cancer. However, the efficacy of selperctinib as a neoadjuvant treatment for locally advanced RET-altered thyroid cancer is unclear.
We report two cases of RET fusion-positive PTC that received neoadjuvant treatment with selperctinib (160 mg twice daily) to reduce the tumor size and enable for radical resection. Tumor sizes were reduced after neoadjuvant treatment with selperctinib. Patients successfully underwent R0 resection with no major surgical complications.
Selperctinib isa potential neoadjuvant treatment for PTC with RET fusion-positive.
局部晚期RET融合阳性的甲状腺乳头状癌（PTC）因肿瘤侵犯关键结构，给手术切除带来重大挑战。新辅助靶向治疗是一种有前景的减轻肿瘤负荷并提高可切除性的方法。塞尔帕替尼是一种RET激酶抑制剂，已被批准用于治疗晚期或转移性RET改变的甲状腺癌。然而，塞尔帕替尼作为局部晚期RET改变的甲状腺癌新辅助治疗的疗效尚不清楚。
我们报告了两例RET融合阳性的PTC患者，他们接受了塞尔帕替尼（每日两次，每次160mg）的新辅助治疗以缩小肿瘤大小并实现根治性切除。塞尔帕替尼新辅助治疗后肿瘤大小减小。患者成功接受了R0切除，无重大手术并发症。
塞尔帕替尼是RET融合阳性PTC的一种潜在新辅助治疗方法。
